Falkson C I, Falkson G, Falkson H C
Department of Medical Oncology, University of Pretoria, South Africa.
Invest New Drugs. 1994;12(3):251-4. doi: 10.1007/BF00873967.
Fotemustine is a novel chloroethylnitrosourea, that readily penetrates the blood brain barrier. Preliminary French studies reported encouraging results with fotemustine in patients with cerebral metastases of malignant melanoma. Thirty-one patients with histologically confirmed metastatic malignant melanoma were entered on a phase II trial. The treatment regimen consisted of fotemustine, administered intravenously as a rapid infusion, at a dose of 100 mg/m2 on day 1, 8 and 15 every 4 to 5 weeks. Objective response (CR + PR) was documented in 3 patients. Median time to treatment failure (TTF) was 44 days and median survival was 164 days. Life threatening toxicity did not occur; hematological toxicity and nausea and vomiting were the most common toxicities. Despite a somewhat disappointing response rate, objective responses were documented in patients with cerebral metastases. Since no other chemotherapeutic agent has shown therapeutic efficacy in cerebral metastases from malignant melanoma fotemustine therefore warrants further study.
福莫司汀是一种新型氯乙基亚硝脲，能轻易穿透血脑屏障。法国的初步研究报告了福莫司汀治疗恶性黑色素瘤脑转移患者的令人鼓舞的结果。31例经组织学确诊为转移性恶性黑色素瘤的患者进入了II期试验。治疗方案包括福莫司汀，每4至5周在第1、8和15天以100mg/m²的剂量静脉快速输注给药。3例患者记录到客观缓解（CR+PR）。治疗失败的中位时间（TTF）为44天，中位生存期为164天。未发生危及生命的毒性；血液学毒性以及恶心和呕吐是最常见的毒性。尽管缓解率有些令人失望，但在脑转移患者中记录到了客观缓解。由于没有其他化疗药物在恶性黑色素瘤脑转移中显示出治疗效果，因此福莫司汀值得进一步研究。
